News

Filter

Current filters:

None

Popular Filters

7857 to 7881 of 8454 results

Vical to earn as much as $130 million from TransVax deal with Astellas

18-07-2011

US drug developer Vical (Nasdaq: VICL) saw its share price leap 11.6% to $4.80 after it revealed that…

Astellas PharmaGlobalLicensingPharmaceuticalResearchTransVaxVaccinesVical

New study shows US Medicare Part D Rx drug costs see significant decline

17-07-2011

The average costs for medicines frequently used by the USA’s Medicare Part D beneficiaries have…

HealthcareNorth AmericaPharmaceuticalPricing

Roche to file for approval of pertuzumab, which does well as combo in Ph III breast cancer trial

17-07-2011

Swiss drug major Roche (ROG: SIX) says it plans to seek approval of its monoclonal antibody pertuzumab…

OncologypertuzumabPharmaceuticalRegulationResearchRoche

Par Pharma branded business faces setback, say Zacks analysts

17-07-2011

US drugmaker Par Pharmaceuticals’ (NYSE: PRX) proprietary products division, Strativa Pharmaceuticals,…

FinancialGenericsOncologyPar PharmaceuticalsPharmaceuticalStrativa PharmaceuticalsZuplenz

Private health care market in Poland to be worth over $12 billion in 2013

17-07-2011

The value of the private health care segment in Poland increased by about 4% year-on-year in 2010, to…

EuropeHealthcarePharmaceutical

European Commission and Australia OK Bristol-Myers Yervoy and Novo Nordisk’s FlexTouch

15-07-2011

Following a recent positive recommendation from the European Medicine Agency’s advisory panel, Bristol-Myers…

Bristol-Myers SquibbDiabetesEuropeFlexTouchNovo NordiskOncologyPharmaceuticalRegulationYervoy

German pharma counts cost of drug price controls, calls for review

15-07-2011

The clamour against the recent drug pricing reforms in Germany has grown steadily louder. Last week Eli…

EuropeFinancialPharmaceuticalPoliticsPricingResearch

Two key validation steps for Livatag achieved by BioAlliance Pharma

15-07-2011

French orphan cancer drug developer BioAlliance Pharma (Euronext Paris: BIO) has announced the validation…

BioAlliance PharmaLivatagOncologyPharmaceuticalRegulationResearch

API production in Russia: scarce but slowly developing

14-07-2011

Over the past few years a trend toward slow development has been observed on the part of producers of…

EuropeGenericsMarkets & MarketingPharmaceuticalRegulationResearch

New pan-Canadian cancer drug review process gets underway

14-07-2011

Cancer patients and clinicians in Canadians are set to benefit from the implementation of the pan-Canadian…

North AmericaOncologyPharmaceuticalPricingRegulation

Japan and China dominate Asian API market

14-07-2011

The market for active pharmaceutical ingredients (APIs) is highest in the USA, followed by Europe and…

Asia-PacificGenericsMarkets & MarketingPharmaceutical

US generics market, worth $74 billion in 2009, set to grow at 10% CAGR

14-07-2011

The US generics market has shown a solid growth during the past few years backed by factors, such as…

Gastro-intestinalsGenericsMarkets & MarketingNorth America

Eisai gets Chinese rights for Orion’s Fareston and Eldepryl; FDA accepts Dacogen sNDA

14-07-2011

Japanese drug major Eisai (TYO: 4523) has entered into a comprehensive marketing agreement with Finland’s…

DacogenEisaiEldeprylFarestonOrion Pharma

New research shows Gilead’s ARVs prevent HIV infection in heterosexuals

14-07-2011

Results from two African studies of pre-exposure prophylaxis, or PrEP, released yesterday well ahead…

Anti-viralsGilead SciencesPharmaceuticalResearchTruvadaViread

Transcept Pharma expects further FDA delay for Intermezzo NDA

14-07-2011

Following a teleconference with the US Food and Drug Administration, neurosciences company Transcept…

IntermezzoNeurologicalNorth AmericaPharmaceuticalRegulationTranscept Pharmazolpidem

Room for improvement of HTA process to accelerate medicines access

14-07-2011

A new report on Health Technology Assessment (HTA) processes published today highlights significant areas…

Asia-PacificBiotechnologyEuropeNorth AmericaPharmaceuticalRegulation

Sanofi and Regeneron’s sarilumab positive in rheumatoid arthritis Ph IIb trial

14-07-2011

Results from Phase IIb trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab…

Anti-Arthritics/RheumaticsPharmaceuticalRegeneronResearchSanofisarilumab

First meeting of BRICS health ministers brings new leadership to global health

13-07-2011

Universal access to medicines was a key topic of discussion at a meeting this week of health ministers…

GenericsGlobalHealthcarePatentsPolitics

7857 to 7881 of 8454 results

Back to top